» Articles » PMID: 23224319

Distinct Patterns of APP Processing in the CNS in Autosomal-dominant and Sporadic Alzheimer Disease

Abstract

Autosomal-dominant Alzheimer disease (ADAD) is a genetic disorder caused by mutations in Amyloid Precursor Protein (APP) or Presenilin (PSEN) genes. Studies from families with ADAD have been critical to support the amyloid cascade hypothesis of Alzheimer disease (AD), the basis for the current development of amyloid-based disease-modifying therapies in sporadic AD (SAD). However, whether the pathological changes in APP processing in the CNS in ADAD are similar to those observed in SAD remains unclear. In this study, we measured β-site APP-cleaving enzyme (BACE) protein levels and activity, APP and APP C-terminal fragments in brain samples from subjects with ADAD carrying APP or PSEN1 mutations (n = 18), patients with SAD (n = 27) and age-matched controls (n = 22). We also measured sAPPβ and BACE protein levels, as well as BACE activity, in CSF from individuals carrying PSEN1 mutations (10 mutation carriers and 7 non-carrier controls), patients with SAD (n = 32) and age-matched controls (n = 11). We found that in the brain, the pattern in ADAD was characterized by an increase in APP β-C-terminal fragment (β-CTF) levels despite no changes in BACE protein levels or activity. In contrast, the pattern in SAD in the brain was mainly characterized by an increase in BACE levels and activity, with less APP β-CTF accumulation than ADAD. In the CSF, no differences were found between groups in BACE activity or expression or sAPPβ levels. Taken together, these data suggest that the physiopathological events underlying the chronic Aβ production/clearance imbalance in SAD and ADAD are different. These differences should be considered in the design of intervention trials in AD.

Citing Articles

Transmembrane and coiled-coil 2 associates with Alzheimer's disease pathology in the human brain.

Hopkins P, Troakes C, King A, Tear G Brain Pathol. 2024; 35(1):e13290.

PMID: 39084860 PMC: 11669416. DOI: 10.1111/bpa.13290.


Alzheimer's disease linked Aβ42 exerts product feedback inhibition on γ-secretase impairing downstream cell signaling.

Zoltowska K, Das U, Lismont S, Enzlein T, Maesako M, Houser M Elife. 2024; 12.

PMID: 39027984 PMC: 11259434. DOI: 10.7554/eLife.90690.


APP dyshomeostasis in the pathogenesis of Alzheimer's disease: implications for current drug targets.

Sirisi S, Sanchez-Aced E, Belbin O, Lleo A Alzheimers Res Ther. 2024; 16(1):144.

PMID: 38951839 PMC: 11218153. DOI: 10.1186/s13195-024-01504-w.


Alzheimer's disease linked Aβ42 exerts product feedback inhibition on γ-secretase impairing downstream cell signaling.

Zoltowska K, Das U, Lismont S, Enzlein T, Maesako M, Houser M bioRxiv. 2023; .

PMID: 37577527 PMC: 10418207. DOI: 10.1101/2023.08.02.551596.


Lysosomal dysfunction in Down syndrome and Alzheimer mouse models is caused by v-ATPase inhibition by Tyr-phosphorylated APP βCTF.

Im E, Jiang Y, Stavrides P, Darji S, Erdjument-Bromage H, Neubert T Sci Adv. 2023; 9(30):eadg1925.

PMID: 37494443 PMC: 10371027. DOI: 10.1126/sciadv.adg1925.


References
1.
Zhong Z, Ewers M, Teipel S, Burger K, Wallin A, Blennow K . Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry. 2007; 64(6):718-26. DOI: 10.1001/archpsyc.64.6.718. View

2.
Fortea J, Llado A, Bosch B, Antonell A, Oliva R, Molinuevo J . Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations. Neurodegener Dis. 2011; 8(4):202-7. DOI: 10.1159/000322229. View

3.
Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S . Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem. 2005; 280(35):30797-806. DOI: 10.1074/jbc.M505249200. View

4.
Joachim C, Games D, Morris J, Ward P, Frenkel D, Selkoe D . Antibodies to non-beta regions of the beta-amyloid precursor protein detect a subset of senile plaques. Am J Pathol. 1991; 138(2):373-84. PMC: 1886178. View

5.
Guardia-Laguarta C, Pera M, Clarimon J, Molinuevo J, Sanchez-Valle R, Llado A . Clinical, neuropathologic, and biochemical profile of the amyloid precursor protein I716F mutation. J Neuropathol Exp Neurol. 2009; 69(1):53-9. DOI: 10.1097/NEN.0b013e3181c6b84d. View